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Abstract: Neurofibromatosis is a systemic hereditary disorder that mainly affects the skin and 
nervous system. It was identified for the first time by Friedrich Von Recklinghausen, being 
called the Von Recklinghausen syndrome. Some of the clinical symptoms can be visible since 
birth, however, most of them start to show up during childhood and adolescence and, in 
women, phenotype becomes evident during pregnancy, due to the severe hormonal changes 
that occur. 
The goal of this research was to understand the way type I neurofibromatosis can affect the 
oral cavity and how the dental doctor can help. For that, several papers were selected from the 
search on the websites Pubmed, Elsevier and UptoDate using the following keywords: 
neurofibromatosis, oral health, neurofibroma, oral cancer, GTP, type 1 neurofibromatosis.  
Concerning clinical features at the oral cavity, more than one fourth of patients with this 
disorder can show neurofibromas in the mouth, usually isolated. Phenotype can include 
increased fungiform papillae, head and neck polyps, nodules in the posterior portion of the 
back of the tongue, dental mobility caused by lesions in the gingival-dental-alveolar complex, 
changes in the number of teeth, molar retention, dental calculus, aplasia of the second bottom 
molars and advanced periodontal disease. Bone changes can be present like subperiosteal 
erosion, hyperplasia, hypoplasia, dysplasia in the wings of the sphenoid and short size. 
Concerning therapeutic strategies, some studies suggest that proteins of the mTOR pathway 
(mammalian target of rapamycin) can be the target for therapy of this disease in case of 
malignant transformation. 
 
Keywords: “Neurofibromatosis”, “Oral Health”, “Neurofibroma”, “Oral Cancer”, “Type 1 
Neurofibromatosis”, that were interconnected in several ways. 
INTRODUCTION 
Neurofibromatosis (NF) is a systemic hereditary disorder 
mainly affecting the skin and nervous system. 
 
Although its existence has been referred in the 13th century, 
the first published report on neurofibromatosis dates from 
1768 describing an affected individual as a “patient having 
skin neurofibromas transmitted by his father” [1]. In 1882, 
neurofibromatosis was described by Friedrich Von 
Recklinghausen, giving the name to the syndrome [2-4]. 
Riccardi & Kleiner [5] were also some of the first researchers 
studying neurofibromatosis patients, having classified the 
disease according with the intensity/gravity of symptoms in 
each patient (Table 1). 
 
There are several forms of this pathology: type 1 (NF1) that 
is the most studied, type 2 neurofibromatosis (NF2) and 
Schwanomatosis. NF1 represents 85-90% of 
neurofibromatosis cases, having an incidence of one case in 
three thousand births. 
 
NF2 affects mainly the central nervous system while NF1 
interferes with peripheral nerve sheath [1,6]. Incidence of 
NF2 is lower than NF1 and is one in thirty-three thousand 
births [7]. Type 2 neurofibromatosis is caused by mutations 
associated with the NF2 gene located on chromosome 22 
(22q12.2). This gene codes for a protein known as 
schwanomin or merlin whose function is to stablish links 
between glycoproteins of cell membrane and cytoskeleton 
proteins [8]. 
 
Although NF2 patients also show brownish spots, these spots 
have irregular edges and are lighter than the ones shown by 
NF1 patients. As in NF1, NF2 patients can also have 
ophthalmic manifestations like cataracts, retina harmatomas 
and meningioma of the optical nerve [9]. 
 
At last, Schwannomatosis is associated with mutations in the 
IN11/SMARCB1 gene, also present in chromosome 22 [9], 
close to theNF2 gene. In this way, NF2 patients frequently 
show associated schwannomas, including bilateral vestibular 
schwannomas that are essential for diagnosis of the disorder 
[8,9]. 
 
Schwannomas are tumours with origin in Schwann cells both 
in peripheral as well as central nerves. In almost all sporadic 
schwannomas there is inactivation of the two alleles of the 
NF2 gene whatever the location of the tumours. On the other 
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hand, NF2 patients are heterozygous for NF2 gene mutations, 
and the developed tumours exhibit loss or mutation of the 
wild allele. In this way, loss of function of the protein coded 
by the NF2 gene (merlin/schwanomin protein), boosts the 
start and development of all schwannomas [8,10]. 
 
Some clinical symptoms of type 1 neurofibromatosis can be 
present since birth, however, most of them develop during 
childhood and adolescence [1]. 
MATERIALS AND METHODS 
Several searches were performed on websites: Pubmed, B-
On, SciELO, Science Direct and UptoDate, as well as on the 
repository of Medicine Faculty of O’Porto University and 
Fernando Pessoa University. 
 
From this search, papers in Portuguese, English, French and 
Spanish were selected, together with some books to complete 
the search. 
ETHIOLOGY 
Type 1 neurofibromatosis is a disorder with an autosomal 
dominant transmission, complete penetrance and variable 
expression [11]. 
 
After positional cloning, the gene involved in the 
development of this pathology was thought to be present in 
chromosomes 5 or 17 [11]. It was Barker that, in 1987, 
observed a considerable connection between markers of 
chromosome 17 and the NF1 gene [12]. Nowadays, it is 
known that this disease is associated with mutations in the 
long arm of chromosome 17 (17q11.2) [1,10]. The 
International NF1 Genetic Analysis Consortium described 
and named numerous mutations in the NF1 gene, including 
deletions, insertions, splice mutations, aminoacid changes 
and chromosomic rearrangements [11,13]. 
 
The NF1 gene has 60 exons and extends for 350 kb. The 
coding region of this gene has 8454 bp being transcribed in 
the direction centromere-telomere [14-18].  
Transcription of the NF1 gene gives rise to different mRNAs 
by alternative splicing with sizes ranging from 11 to 13 kb, 
leading to multiple isoforms expressed in different tissues 
like neurons, oligodendrocytes and Schwann cells [19]. This 
alternative splicing occurs in exons 9, 23 and 48 [20]. The 
stop codon is present in exon 49 followed by a 3’-untranslated 
region of 3,5 kb [21]. 
 
The 13 kb transcript is the most common and codes for a 
protein of 2818 aminoacids and 220 kDa, known as 
neurofibromin that is expressed in several tissues like brain, 
kidneys, thymus and spleen [19,22,23]. This protein has a 
central domain, codified by exons 21 to 27 of the NF1 gene, 
known as GRD (GAP related domain), of 360 aminoacids, 
homologous to the catalytic domain of the activator protein 
of GTPase [22,24]. 
 
This group of enzymes called GAP act in the regulation of 
several cellular functions including cell growth, signal 
transduction and cytoskeleton organization. The GRD 
domain has an important role in negative regulation of a 
mitogenic signalling pathway mediated by the p21-ras gene 
(proto-oncogene homologous to the oncogene of mouse 
sarcoma) [25]. The Ras protein coded by this gene, attaches 
guanosine triphosphate (GTP) and is involved in the signal 
transduction pathway. The role of neurofibromin, as well as 
the role of the GAP protein, is to interact with Ras linked to 
GTP, being involved in GTP hydrolysis in guanosine 
diphosphate (GDP), with consequent inactivation of the Ras 
protein [20]. As a result, the inactive Ras protein, controls 
cellular growth and multiplication. In this way, the decrease 
in neurofibromin levels resulting from mutations in the 
coding gene, leads to over-activation of the p21-ras gene, 
consequent increase of active Ras protein and subsequent 
disorganized cell growth and tumour development 
(development of neurofibromas) [18]. 
SYSTEMIC TRAITS 
As a result of variable expression, this disorder can lead to the 
development of several degrees of symptoms intensity. For 
this reason, Riccardi & Kleiner [5] stablished several degrees 
of neurofibromatosis (Table 1). 
Table 1. Classification of intensity of Neurofibromatosis according to Riccardi & Kleiner [5]. 
Intensity Clinical traits 
Minimal Brownish spots 
Few skin neurofibromas without aesthetical or functional involvement 
Light Big number of skin neurofibromas 
Asymptomatic internal lesions 
Low aesthetical involvement 
Moderate Big number of skin and visceral neurofibromas 
Pseudarthrosis 
Scoliosis 
Controlled convulsions 
Strong Big health involvement 
Frequent surgical interventions 
Symptoms associated with several types of cancer like intracranial and spinal tumour, malignant schwannoma, 
neurofibersarcoma, uncontrolled convulsions, mental retardation, hydrocephaly, progressive hypertrophies. 
 
According with the National Institute of Health (NHI) of 
USA, for NF1 diagnosis, the patient must show two or more 
of the following characteristics [11,26]: 
i) Six or more brownish spots 
ii) Two or more neurofibromas of any type or one plexiform 
neurofibroma; false eels in the axillar or inguinal region 
iii) Optic glioma 
iv) One distinct bone lesion, like sphenoid dysplasia or 
thinning of long bones with or without pseudarthrosis 
v) A first degree relative having NF1, according with the 
stablished criteria. 
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Pathognomonic characteristics of the disease are easy to 
diagnose and include brownish spots present in skin of most 
patients [1,13,27]. According with Crowe criteria [4], to be 
considered a neurofibromatosis phenotype the patient must 
show six or more spots with a diameter bigger than 1,5 cm in 
adults and 0,5 cm in children [1,27]. 
 
Another typical characteristic is the presence of 
neurofibromas. As previously referred, for diagnosis of 
neurofibromatosis, a patient must have two or more 
neurofibromas of any type or a plexiform neurofibroma with 
itching. These manifestations can be circumscribed to just a 
segment of nervous distribution, while plexiform 
neurofibromatosis is usually distributed close to nerves, 
having easy relapse after surgical removal [27,28]. 
Sometimes, itching intensity is proportional to the size and 
number of neurofibromas. Heat increases itching, and cold 
water relieves [27]. Lesions in the peripheral nervous system 
can affect the functioning of the stomatognatic system, as 
described above. 
 
Moreover, these patients frequently show Lish nodules in the 
anterior face of iris, that are pigmented focal malformations 
like benign tumours called harmatomas [1,27]. These 
structures can have a colour from yellow to light brown and 
are formed by melanocytes with neural crest origin [1,29]. 
 
The most common SNC tumour associated with NF1 is the 
optic glioma [13], being astrocytomas (tumours associated 
with astrocytes) the most frequent [30]. The anterior visual 
path is most frequently affected. NF1 patients usually present 
one unilateral glioma [13]. In very severe NF1 cases, affected 
individuals can show high commitment of vision due to 
ocular neurofibromas [28,31]. 
 
The sphenoid wing dysplasia is congenital and usually 
unilateral and non-evolutionary. It is normally associated 
with a plexiform orbital neurofibroma [32]. According with 
Burrows [33], NF patients can show dysplasia in the wings of 
the sphenoid bone affecting the orbit wall and the torsal seal, 
thus manifesting exophthalmia resulting from the herniation 
of the dura into the orbit [31,33]. 
NF1 patients can also show dysplasia in long bones, being 
tibia the most affected, often showing fractures with 
secondary pseudarthrosis [32]. 
 
Concerning non-pathognomic symptoms, the most usual are 
visceral, neoplastic and bone manifestations, besides the ones 
already mentioned before [27]. 
 
Visceral manifestations can vary according with the location 
of neurofibromas. When they are close to the stomach or 
ileum, patients can present digestive complications [27]. 
 
Patients with neurofibromatosis showing changes in the 
endocrine system, can develop scoliosis, short size with an 
increase in the chance of bone fracture [13]. Neoplastic 
complications, besides optical neurofibromas and gliomas 
previously referred, also include other tumours that can 
associated with NF1, as can be checked in Riccardi & 
Kleiner’s scale (Table 1). More severe complications can 
occur by the development of Malignant Peripheral Nerve 
Sheat Tumour (MPNST), name given to malign tumours or 
neural origin [6]. MPNST can appear de novo or be a 
consequence of malign transformation of pre-existing 
neurofibromas. De novo tumours can develop all over the 
body while the associated with neurofibromas have a more 
centralized location. As a rule, these MPNST are 
hypercellular, hyperchromatic and cells with mitotic spindle 
and sometimes present a fasciculated pattern similar to 
fishbone [31]. Öztürk & Tutkun [6] reported a case of a 16-
year-old male patient who presented a severe dysphagia, 
mandibular and temporomandibular pain and respiratory 
difficulty due to a MDNST of the retromolar area. 
 
Concerning bone growth, some authors suggest that this may 
result from tumour development inside the bone or in bone 
direction resulting in bone reabsorption or hypoplasia [4]. 
Other studies suggest that the presence of a tumour adjacent 
to the bone can stimulate bone growth resulting in a 
hyperplasia. However, bone complications might appear by 
dysplasia not related to its proximity with the bone tissue, as 
the cases of mesodermal dysplasia. Based on presented data, 
it is believed that neurofibromatosis might have neuro-
ectoderm or mesoderm origin [4,34]. 
Oral cavity manifestations: 
Other typical symptoms seen in the oral cavity are increased 
fungiform papillas, nodules in the posterior portion on the 
back of the tongue, teeth mobility as a result of lesions in the 
gingival-dental-alveolar complex, change in teeth number, 
molar retention, dental calculus, aplasia of the second inferior 
molars and advanced periodontal disease [35]. Tongue and 
oral mucosa are the most affected regions. Shapiro et al. [34] 
detected oral neurofibromas in soft tissues in 6 of 22 analysed 
patients. 
 
Neurofibromas present in the trigeminal nerve can affect 
sensorial capacities of the patient, while if they are present in 
the facial or hypoglossal nerves, might compromise his motor 
functions [34]. Moreover, a plexiform neurofibroma in the 
trigeminal nerve is frequently the main cause of hemifacial 
disfiguration observed in patients [29]. Pain and paraesthesia 
are characteristic of an affected inferior dental nerve. Since 
neurofibromas are benign tumours, they show slow growth. 
During its growth, it moves the nerve laterally giving pain or 
paraesthesia. However, cases with fast development of the 
neurofibroma can be a sign of haemorrhagy or sarcomatosa 
malignant degeneration [27]. 
 
The increase of mandibular canal, mandibular and mental 
foramen are some of the radiographic findings that can point 
to Von Reckling Hausen disease [29]. The most common 
craniofacial change is the skull increase, as a result of the 
higher production of glia cells. Among bad bone formations, 
it is also possible to see mandibula hypoplasia, decrease or 
elongation of the coronoid process and zygomatic arch [36]. 
 
Due to growth of neurofibromas in parapharynx space, 
patients may also present hoarseness, dysphagia and tongue 
atrophy by paresis of the last four pairs of cranial nerves 
(glossopharyngeal, vagus, accessory and hypoglossal) [36]. 
Souza et al. [3] observed that 56,7% of NF1 patients (183 of 
206) showed changes in voice and oral motor. It is believed 
that those changes result from neurological disturbances that 
give rise to insufficiency of velopharyngeal muscle and 
oropharyngeal musculature. The same study also observed 
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that 67% of individuals diagnosed with NF1 showed less 
muscular strength when compared with undiagnosed 
individuals [3]. These patients can show nasal and week 
speech with stimulated rhythm and defect in sibilant sounds 
pronunciation [36]. 
 
Although several oral manifestations associated with NF1 are 
known, very few cases of hyposalivation and xerostomia have 
been reported in literature. Cunha et al. [37] performed a case-
control study with 49 individuals diagnosed with NF1 and a 
control group of 40 individuals not diagnosed with NF1. They 
observed that NF1 patients had higher prevalence of 
hyposalivation when compared with the control group [37]. 
 
Transformation of plexiform neurofibromas into malignant 
tumours compromises prognosis. In these cases, surgical 
resection complemented with radiotherapy or chemotherapy 
is the indicated treatment [36]. 
DIAGNOSIS 
Clinical diagnosis of NF1, as previously mentioned, is 
performed according with the phenotypic characteristics 
established by the National Institute of Health (NIH) of USA 
shown in Table 1. When an individual shows only some of 
the traits, NF1 diagnosis cannot be established or discarded. 
 
Hence, other exams can be done as a diagnosis complement, 
namely computer tomography, proton spectroscopy to 
evaluate brain metabolites, image magnetic resonance, 
neurofibromas biopsy, skin exams of hyperpigmentation 
using a Wood lamp, IQ test, psychological analysis, 
ophthalmologic exam and auditive evaluation [38]. 
 
In cases of pregnancy where one of the parents is affected by 
NF1, it is useful the use of genetic tests for mutation screening 
of NF1 gene. Among these tests are conformational 
polymorphism analysis of single strand and of heteroduplex, 
FISH, electrophoresis in temperature gradient gel or 
denaturing gel and the protein truncation test [11]. Samples 
can be obtained from the amniotic fluid or chorionic villi [11]. 
TREATMENT 
Clinically, neurofibromas are a sessile and pedunculated 
mass of fibrous consistency with slow growth [39]. 
Histologically, they are composed of bundles of spindle-
shaped cells with undulated nucleus and having a variable 
amount of myxoid material [40]. 
 
Prognosis and treatment depend on compromised systems 
and tissues. Due to potential relapse, surgical removal is 
mostly performed in cases with high aesthetic and functional 
commitment or with tendency for malignant tumours 
transformation [36,41]. 
 
During this procedure, major nervous structures should be 
kept since surgical excisions do not have as goal to induce 
neoplastic changes. Some factors like neurofibromas 
infiltrations, blood vessels hypertrophy and abnormal 
response to muscle relaxants anaesthetics recently reported 
can prevent surgery [36]. 
 
So far, there is still no pharmacological treatment for NF1. 
However, itis believed that proteins of the mTOR pathway 
(mammalian target of rapamycin) can act as a therapy for this 
disease, since they have a crucial role in regulation of tumour 
cells division and growth of blood vessels [42,43]. The 
mTOR protein is a serine/threonine kinase that besides its 
action in cellular growth, plays an important role during 
protein synthesis. Changes in this signalling pathway are 
associated with tumorigenesis, angiogenesis, tumour growth 
and metastization. Inactivation of certain tumour suppressor 
genes leads to activation of the mTOR pathway, as is the case 
of p53 gene. The first discovered inhibitor of this pathway 
was rapamycin, however, analogues of this were developed 
due to its pharmacokinetics and pharmacodynamics 
properties [8,42,44,45]. 
 
In cases of neurofibromas that are not associated with Von 
Reclinghausen syndrome, other techniques have been 
developed. In a study of Angiero et al. [46] ten individuals 
having neurofibromas in different places of the oral cavity 
were submitted to a treatment of diode laser with a wave 
length of 980 nm, 2.0 W, optical fibre of 320 µ, for an 
exposure period of 45 seconds in average, at a distance of 1 
cm from the source. After 15 days, all patients showed cure, 
and only half of them felt a slight discomfort after surgery. 
This technique allows an easier excision of soft tissues than 
surgical intervention. However, the risk of necrosis, 
ulceration and drilling of tissues is bigger due to the chance 
of contact between the laser and adjacent mucosa, being 
required to keep refrigeration of the mucosa [46]. 
CONCLUSION 
Neurofibromatosis type 1 is a hereditary disease associated 
with a gene present in chromosome 17. This disorder affects 
multiple organs including the stomatognatic system. Due to 
the typical phenotype observed in patients, this disease has a 
big impact on patient’s life from the clinical and 
psychological points of view, since the aesthetic condition 
might lead to low self-esteem. 
 
Therefore, it is very important that doctors are aware of this 
condition since different degrees of symptomatology might 
be present, due to the variable expressivity shown in this 
disorder. 
 
NF1 treatment depends on which systems and/or tissues are 
affected. No pharmacological treatment is available and 
surgical removal of neurofibromas is usually performed in 
patients with high aesthetic and functional commitment or 
with tendency for malignant tumours transformation, due to 
frequent relapse. 
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